$FBRX
Forte Biosciences, Inc.

2018 Q2 Form 10-Q Financial Statement

#000156459018021106 Filed on August 09, 2018

View on sec.gov

Income Statement

Concept 2018 Q2 2017 Q2
Revenue $9.000K $10.00K
YoY Change -10.0% 0.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.570M $2.030M
YoY Change 26.6% 84.55%
% of Gross Profit
Research & Development $12.76M $6.632M
YoY Change 92.45% 1.56%
% of Gross Profit
Depreciation & Amortization $120.0K $60.00K
YoY Change 100.0% 0.0%
% of Gross Profit
Operating Expenses $15.34M $8.662M
YoY Change 77.05% 13.48%
Operating Profit -$15.33M -$8.652M
YoY Change 77.15%
Interest Expense -$760.0K -$410.0K
YoY Change 85.37% -2.38%
% of Operating Profit
Other Income/Expense, Net -$762.0K
YoY Change
Pretax Income -$16.09M -$9.070M
YoY Change 77.4% 12.81%
Income Tax
% Of Pretax Income
Net Earnings -$16.09M -$9.066M
YoY Change 77.47% 12.73%
Net Earnings / Revenue -178766.67% -90660.0%
Basic Earnings Per Share
Diluted Earnings Per Share -$12.10M -$8.321M
COMMON SHARES
Basic Shares Outstanding 19.81M
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q2 2017 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $79.46M $108.6M
YoY Change -26.83%
Cash & Equivalents $24.61M $76.10M
Short-Term Investments $54.85M $32.54M
Other Short-Term Assets $4.000M $1.000M
YoY Change 300.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $83.50M $109.6M
YoY Change -23.81%
LONG-TERM ASSETS
Property, Plant & Equipment $3.700M $900.0K
YoY Change 311.11%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $200.0K $300.0K
YoY Change -33.33%
Total Long-Term Assets $3.800M $1.200M
YoY Change 216.67%
TOTAL ASSETS
Total Short-Term Assets $83.50M $109.6M
Total Long-Term Assets $3.800M $1.200M
Total Assets $87.30M $110.8M
YoY Change -21.21%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.500M $1.300M
YoY Change 15.38%
Accrued Expenses $11.20M $6.700M
YoY Change 67.16%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $7.200M
YoY Change
Total Short-Term Liabilities $13.77M $15.20M
YoY Change -9.43%
LONG-TERM LIABILITIES
Long-Term Debt $25.91M $6.900M
YoY Change 275.55%
Other Long-Term Liabilities $1.600M $100.0K
YoY Change 1500.0%
Total Long-Term Liabilities $25.91M $7.000M
YoY Change 270.19%
TOTAL LIABILITIES
Total Short-Term Liabilities $13.77M $15.20M
Total Long-Term Liabilities $25.91M $7.000M
Total Liabilities $41.25M $22.20M
YoY Change 85.8%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $46.09M $88.60M
YoY Change
Total Liabilities & Shareholders Equity $87.30M $110.8M
YoY Change -21.21%

Cashflow Statement

Concept 2018 Q2 2017 Q2
OPERATING ACTIVITIES
Net Income -$16.09M -$9.066M
YoY Change 77.47% 12.73%
Depreciation, Depletion And Amortization $120.0K $60.00K
YoY Change 100.0% 0.0%
Cash From Operating Activities -$10.76M -$7.350M
YoY Change 46.39% -5.53%
INVESTING ACTIVITIES
Capital Expenditures -$660.0K -$60.00K
YoY Change 1000.0% -50.0%
Acquisitions
YoY Change
Other Investing Activities $1.450M -$10.60M
YoY Change -113.68% -226.04%
Cash From Investing Activities $790.0K -$10.65M
YoY Change -107.42% -228.47%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 16.79M 87.16M
YoY Change -80.74% -290633.33%
NET CHANGE
Cash From Operating Activities -10.76M -7.350M
Cash From Investing Activities 790.0K -10.65M
Cash From Financing Activities 16.79M 87.16M
Net Change In Cash 6.820M 69.16M
YoY Change -90.14% 14308.33%
FREE CASH FLOW
Cash From Operating Activities -$10.76M -$7.350M
Capital Expenditures -$660.0K -$60.00K
Free Cash Flow -$10.10M -$7.290M
YoY Change 38.55% -4.83%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q2 us-gaap Operating Expenses
OperatingExpenses
15336000
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-15327000
us-gaap Depreciation
Depreciation
127000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1532000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-684000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2035000
us-gaap Share Based Compensation
ShareBasedCompensation
3193000
us-gaap Share Based Compensation
ShareBasedCompensation
1585000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
15018000
CY2018Q2 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseMember
CY2017Q2 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseMember
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2018Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1036000
CY2018Q2 toca Deferred Grant Funding
DeferredGrantFunding
22000
CY2018Q2 us-gaap Liabilities Current
LiabilitiesCurrent
13766000
CY2018Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
25913000
CY2018Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
18000
CY2018Q2 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1550000
CY2018Q2 us-gaap Liabilities
Liabilities
41247000
CY2018Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2018Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2018Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19951158
CY2018Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19951158
CY2018Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
9000
CY2017Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10000
CY2018Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12763000
CY2017Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6632000
CY2017Q2 us-gaap Operating Expenses
OperatingExpenses
8662000
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-8652000
CY2018Q2 us-gaap Interest Income Other
InterestIncomeOther
331000
us-gaap Depreciation
Depreciation
222000
us-gaap Paid In Kind Interest
PaidInKindInterest
873000
us-gaap Paid In Kind Interest
PaidInKindInterest
293000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
86000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
13000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-207000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-534000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1621000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
982000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-21000
toca Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
496000
toca Increase Decrease In Deferred Grant Funding
IncreaseDecreaseInDeferredGrantFunding
-1000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-23471000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
26454000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
28444000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
877000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
20000
toca Proceeds From Issuance Of Notes Payable Net Of Issuance Costs
ProceedsFromIssuanceOfNotesPayableNetOfIssuanceCosts
26325000
us-gaap Payments Of Debt Extinguishment Costs
PaymentsOfDebtExtinguishmentCosts
8631000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
3000000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
3600000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
324000
toca Proceeds From Offering Of Common Net Of Stock Issuance Costs
ProceedsFromOfferingOfCommonNetOfStockIssuanceCosts
88615000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
7338000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
92400000
toca Allowance For Tenant Improvements
AllowanceForTenantImprovements
1054000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
733000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
158000
toca Fair Value Of Common Stock Warrants Issued In Connection With Notes Payable
FairValueOfCommonStockWarrantsIssuedInConnectionWithNotesPayable
479000
toca Convertible Preferred Stock Converted Into Shares Of Common Stock
ConvertiblePreferredStockConvertedIntoSharesOfCommonStock
131410000
toca Convertible Promissory Notes Principal And Accrued Interest Converted Into Shares Of Common Stock
ConvertiblePromissoryNotesPrincipalAndAccruedInterestConvertedIntoSharesOfCommonStock
11092000
toca Preferred Stock Warrants Liabilities Converted Into Warrants To Purchase Share Of Common Stock
PreferredStockWarrantsLiabilitiesConvertedIntoWarrantsToPurchaseShareOfCommonStock
89000
toca Deferred Equity Issuance Cost Payment Reclassified Of Equity Effective Intial Public Offering
DeferredEquityIssuanceCostPaymentReclassifiedOfEquityEffectiveIntialPublicOffering
1574000
toca Deferred Debt And Equity Issuance Costs Incurred But Not Yet Paid
DeferredDebtAndEquityIssuanceCostsIncurredButNotYetPaid
99000
us-gaap Initial Offering Period
InitialOfferingPeriod
April 19, 2017
CY2017Q2 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
86900000
CY2018Q2 toca Working Capital
WorkingCapital
69700000
CY2018Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
79500000
CY2018Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3616085
CY2017Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2551556
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3616085
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2551556
CY2018Q2 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2017Q2 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2018Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
54903000
CY2018Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
55000
CY2017Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
31000
CY2018Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
54848000
CY2017Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
52792000
us-gaap Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net
OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet
0
CY2018Q2 toca Accrued Clinical Trial Expenses Current
AccruedClinicalTrialExpensesCurrent
4816000
CY2018Q2 toca Accrued Contract Manufacturing Services Current
AccruedContractManufacturingServicesCurrent
2518000
CY2018Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1563000
CY2017Q4 us-gaap Interest Payable Current
InterestPayableCurrent
77000
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
276000
CY2018Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2041000
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
933000
CY2018Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
4295319
CY2018Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1672000
CY2017Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1056000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3193000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1585000

Files In Submission

Name View Source Status
0001564590-18-021106-index-headers.html Edgar Link pending
0001564590-18-021106-index.html Edgar Link pending
0001564590-18-021106.txt Edgar Link pending
0001564590-18-021106-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
toca-10q_20180630.htm Edgar Link pending
toca-20180630.xml Edgar Link completed
toca-20180630.xsd Edgar Link pending
toca-20180630_cal.xml Edgar Link unprocessable
toca-20180630_def.xml Edgar Link unprocessable
toca-20180630_lab.xml Edgar Link unprocessable
toca-20180630_pre.xml Edgar Link unprocessable
toca-ex101_414.htm Edgar Link pending
toca-ex102_197.htm Edgar Link pending
toca-ex103_192.htm Edgar Link pending
toca-ex311_7.htm Edgar Link pending
toca-ex312_8.htm Edgar Link pending
toca-ex321_9.htm Edgar Link pending
toca-ex46_196.htm Edgar Link pending
toca-ex47_195.htm Edgar Link pending
toca-ex48_194.htm Edgar Link pending
toca-ex49_193.htm Edgar Link pending